Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up

BACKGROUND: Vaccination remains the primary measure to prevent the spread of the SARS-CoV-2 virus, further necessitating the use of effective licensed vaccines. METHODS: From Dec 25, 2020, to July 11, 2021, we conducted a multicenter, randomised, single-blind, placebo-controlled phase 3 efficacy tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Khairullin, Berik, Zakarya, Kunsulu, Orynbayev, Mukhit, Abduraimov, Yergali, Kassenov, Markhabat, Sarsenbayeva, Gulbanu, Sultankulova, Kulyaisan, Chervyakova, Olga, Myrzakhmetova, Balzhan, Nakhanov, Aziz, Nurpeisova, Ainur, Zhugunissov, Kuandyk, Assanzhanova, Nurika, Nurabayev, Sergazy, Kerimbayev, Aslan, Yershebulov, Zakir, Burashev, Yerbol, Kulmagambetov, Ilyas, Davlyatshin, Timur, Sergeeva, Maria, Buzitskaya, Zhanna, Stukova, Marina, Kutumbetov, Lespek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233449/
https://www.ncbi.nlm.nih.gov/pubmed/35770251
http://dx.doi.org/10.1016/j.eclinm.2022.101526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233449/
https://www.ncbi.nlm.nih.gov/pubmed/35770251
http://dx.doi.org/10.1016/j.eclinm.2022.101526

Ejemplares similares